Journal
PHARMACOLOGY & THERAPEUTICS
Volume 178, Issue -, Pages 132-140Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2017.04.002
Keywords
Antimicrobial peptides (AMPs); Synthetic peptides; Antibiotic resistance; Immune modulation; Infectious diseases; Inflammation; Vitamin D; Host-directed therapy
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia - Ministerio da Ciencia, Tecnologia
- CNPq
- CAPES
- FADPDF
- FINEP
- FUNDECT
- Ramon Areces Foundation (Spain)
- National Council of Technological and Scientific Development (CNPq)
- Fundacao Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) [300583/2016-8]
- National Institutes of Health [1P50GM098792, 1R21AI12166901]
- National Science Foundation [MCB-1350625]
- Defense Threat Reduction Agency [HDTRA1-14-1-0007, HDTRA1-15-1-0050]
- Defense Advanced Research Projects Agency
- Office of Naval Research
- Army Research Office
- Center for Microbiome Informatics and Therapeutics
- Broad Institute of MIT and Harvard
- Koch Institute for Integrative Cancer Research
- Kuwait-MIT Center for Natural Resources and Environment
Ask authors/readers for more resources
Antimicrobial peptides (AMPs) have evolved through billions of years as part of our innate immune system. These agents are produced by various cells throughout the human body and play important roles in our ability to respond to infections. In this review, we outline evidence linking AMP expression with a range of inflammatory and autoimmune human diseases. Finally, we highlight the promise of endogenous AMP induction for the treatment of disease (i.e., host-directed therapy) and briefly mention the different peptide drugs that are currently undergoing clinical trials. (C) 2017 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
